267 related articles for article (PubMed ID: 38393907)
1. A Chronic Increase in Blood-Brain Barrier Permeability Facilitates Intraneuronal Deposition of Exogenous Bloodborne Amyloid-Beta1-42 Peptide in the Brain and Leads to Alzheimer's Disease-Relevant Cognitive Changes in a Mouse Model.
Acharya NK; Grossman HC; Clifford PM; Levin EC; Light KR; Choi H; Swanson Ii RL; Kosciuk MC; Venkataraman V; Libon DJ; Matzel LD; Nagele RG
J Alzheimers Dis; 2024; 98(1):163-186. PubMed ID: 38393907
[TBL] [Abstract][Full Text] [Related]
2. Evidence that Brain-Reactive Autoantibodies Contribute to Chronic Neuronal Internalization of Exogenous Amyloid-β1-42 and Key Cell Surface Proteins During Alzheimer's Disease Pathogenesis.
Goldwaser EL; Acharya NK; Wu H; Godsey GA; Sarkar A; DeMarshall CA; Kosciuk MC; Nagele RG
J Alzheimers Dis; 2020; 74(1):345-361. PubMed ID: 32039847
[TBL] [Abstract][Full Text] [Related]
3. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons.
Clifford PM; Zarrabi S; Siu G; Kinsler KJ; Kosciuk MC; Venkataraman V; D'Andrea MR; Dinsmore S; Nagele RG
Brain Res; 2007 Apr; 1142():223-36. PubMed ID: 17306234
[TBL] [Abstract][Full Text] [Related]
4. Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-β(1-42) deposition.
Nagele RG; Clifford PM; Siu G; Levin EC; Acharya NK; Han M; Kosciuk MC; Venkataraman V; Zavareh S; Zarrabi S; Kinsler K; Thaker NG; Nagele EP; Dash J; Wang HY; Levitas A
J Alzheimers Dis; 2011; 25(4):605-22. PubMed ID: 21483091
[TBL] [Abstract][Full Text] [Related]
5. High-Density Lipoprotein Mimetic Peptide 4F Efficiently Crosses the Blood-Brain Barrier and Modulates Amyloid-
Swaminathan SK; Zhou AL; Ahlschwede KM; Curran GL; Lowe VJ; Li L; Kandimalla KK
J Pharmacol Exp Ther; 2020 Nov; 375(2):308-316. PubMed ID: 32778535
[TBL] [Abstract][Full Text] [Related]
6. Amyloid-Beta Peptides 40 and 42 Employ Distinct Molecular Pathways for Cell Entry and Intracellular Transit at the Blood-Brain Barrier Endothelium.
Wang Z; Sharda N; Omtri RS; Li L; Kandimalla KK
Mol Pharmacol; 2023 Nov; 104(5):203-213. PubMed ID: 37541759
[TBL] [Abstract][Full Text] [Related]
7. Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).
Do TM; Dodacki A; Alata W; Calon F; Nicolic S; Scherrmann JM; Farinotti R; Bourasset F
J Alzheimers Dis; 2016; 49(2):287-300. PubMed ID: 26484906
[TBL] [Abstract][Full Text] [Related]
8. Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib.
Acharya NK; Levin EC; Clifford PM; Han M; Tourtellotte R; Chamberlain D; Pollaro M; Coretti NJ; Kosciuk MC; Nagele EP; Demarshall C; Freeman T; Shi Y; Guan C; Macphee CH; Wilensky RL; Nagele RG
J Alzheimers Dis; 2013; 35(1):179-98. PubMed ID: 23388174
[TBL] [Abstract][Full Text] [Related]
9. Enhanced neprilysin-mediated degradation of hippocampal Aβ42 with a somatostatin peptide that enters the brain.
Rofo F; Ugur Yilmaz C; Metzendorf N; Gustavsson T; Beretta C; Erlandsson A; Sehlin D; Syvänen S; Nilsson P; Hultqvist G
Theranostics; 2021; 11(2):789-804. PubMed ID: 33391505
[No Abstract] [Full Text] [Related]
10. Distinct Effects of Beta-Amyloid, Its Isomerized and Phosphorylated Forms on the Redox Status and Mitochondrial Functioning of the Blood-Brain Barrier Endothelium.
Petrovskaya AV; Tverskoi AM; Barykin EP; Varshavskaya KB; Dalina AA; Mitkevich VA; Makarov AA; Petrushanko IY
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613623
[TBL] [Abstract][Full Text] [Related]
11. Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons.
D'Andrea MR; Nagele RG
Curr Pharm Des; 2006; 12(6):677-84. PubMed ID: 16472157
[TBL] [Abstract][Full Text] [Related]
12. Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism.
Ma Q; Zhao Z; Sagare AP; Wu Y; Wang M; Owens NC; Verghese PB; Herz J; Holtzman DM; Zlokovic BV
Mol Neurodegener; 2018 Oct; 13(1):57. PubMed ID: 30340601
[TBL] [Abstract][Full Text] [Related]
13. Active full-length DNA Aβ
Rosenberg RN; Fu M; Lambracht-Washington D
Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
[TBL] [Abstract][Full Text] [Related]
14. Insulin Signaling Differentially Regulates the Trafficking of Insulin and Amyloid Beta Peptides at the Blood-Brain Barrier.
Zhou AL; Swaminathan SK; Salian VS; Wang L; Curran GL; Min HK; Lowe VJ; Kandimalla KK
Mol Pharm; 2024 May; 21(5):2176-2186. PubMed ID: 38625027
[TBL] [Abstract][Full Text] [Related]
15. Blood-Brain Barrier Permeable Chitosan Oligosaccharides Interfere with β-Amyloid Aggregation and Alleviate β-Amyloid Protein Mediated Neurotoxicity and Neuroinflammation in a Dose- and Degree of Polymerization-Dependent Manner.
Zhu L; Li R; Jiao S; Wei J; Yan Y; Wang ZA; Li J; Du Y
Mar Drugs; 2020 Sep; 18(10):. PubMed ID: 32992800
[TBL] [Abstract][Full Text] [Related]
16. Blood-brain barrier integrity impacts the use of plasma amyloid-β as a proxy of brain amyloid-β pathology.
Bellaver B; Puig-Pijoan A; Ferrari-Souza JP; Leffa DT; Lussier FZ; Ferreira PCL; Tissot C; Povala G; Therriault J; Benedet AL; Ashton NJ; Servaes S; Chamoun M; Stevenson J; Rahmouni N; Vermeiren M; Macedo AC; Fernández-Lebrero A; García-Escobar G; Navalpotro-Gómez I; Lopez O; Tudorascu DL; Cohen A; Villemagne VL; Klunk WE; Gauthier S; Zimmer ER; Karikari TK; Blennow K; Zetterberg H; Suárez-Calvet M; Rosa-Neto P; Pascoal TA
Alzheimers Dement; 2023 Sep; 19(9):3815-3825. PubMed ID: 36919582
[TBL] [Abstract][Full Text] [Related]
17. Annexin A1 restores Aβ
Park JC; Baik SH; Han SH; Cho HJ; Choi H; Kim HJ; Choi H; Lee W; Kim DK; Mook-Jung I
Aging Cell; 2017 Feb; 16(1):149-161. PubMed ID: 27633771
[TBL] [Abstract][Full Text] [Related]
18. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding.
Shackleton B; Crawford F; Bachmeier C
Fluids Barriers CNS; 2016 Aug; 13(1):14. PubMed ID: 27503326
[TBL] [Abstract][Full Text] [Related]
20. Distinct Uptake Kinetics of Alzheimer Disease Amyloid-
Sharda N; Ahlschwede KM; Curran GL; Lowe VJ; Kandimalla KK
J Pharmacol Exp Ther; 2021 Mar; 376(3):482-490. PubMed ID: 33303699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
